LabCorp inks a testing deal; AstraZeneca moves away from contract manufacturing;

> LabCorp ($LH), owner of Covance, signed a deal with regenerative medicine outfit ORIG3N to handle clinical storage and testing. More

> AstraZeneca ($AZN) is bringing more of its biologics manufacturing in-house, laying out $285 million for a new plant in Sweden. Story

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.